argenx SE

Report Publication Announcement • Mar 9, 2017

argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2016 Financial Results on March 15, 2017

8 March 2017

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Wednesday, March 15, 2017 at 3:00 pm CET (10:00 am EDT) to discuss the 2016 financial results, as well as provide a fourth quarter business update.

To participate in the conference call, please select your phone number below, and use the confirmation code 75576807. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

A replay of the webcast will also be available on the argenx website.

About argenx

argenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibodybased therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.

www.argenx.com

Dial-In Numbers:

Participant Free Call Dial-In Numbers: UK 0800 694 0257

Participant Standard International Dial-In: UK Standard International +44 (0) 1452 555 566

Participant UK Local Call Dial-In Numbers: UK 0844 493 3800 UK National Call 0871 700 0345

Participant Local Call Dial-In Numbers: Australia 0290 371 687

Austria	0192 865 68
Belgium	0817 000 61
Croatia	0177 766 11
Czech Republic	2288 804 60
Denmark	3272 7625
Finland	0923 195 187
France	0176 742 428
Germany	0692 222 3479
Germany	0692 222 4918
Hungary	0618 088 303
India	0223 098 5304
Ireland	0143 196 48
Ireland	0150 601 53
Italy	0236 008 146
Latvia	6778 2516
Luxembourg	2088 0695
Netherlands	0207 176 886
New Zealand	0992 917 07
Norway	2156 3013
Poland	2230 701 18
Romania	0318 144 957
Russia	4996 771 036
Slovenia	0160 093 64
South Africa	2110 032 02
Spain	9141 436 69
Sweden	0850 336 434
Switzerland	0565 800 007
USA	1631 510 7498

For further information, please contact:

Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 243 40 70 info@argenx.com

Beth DelGiacco (US IR) Stern Investor Relations +1 212 362 1200 beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those

predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.